Autolus Therapeutics Plc logo

Autolus Therapeutics Plc Share Price (NASDAQ: AUTL)

$1.66

-0.09

(-5.14%)

Live

Last updated on

Check the interactive Autolus Therapeutics Plc Stock chart to analyse performance

Autolus Therapeutics Plc stock performance

as on August 26, 2025 at 12:45 AM IST

  • Today's Low:$1.66
    Today's High:$1.77

    Day's Volatility :6.5%

  • 52 Weeks Low:$1.11
    52 Weeks High:$5.00

    52 Weeks Volatility :77.9%

Autolus Therapeutics Plc Stock Returns

PeriodAutolus Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
11.46%
6.0%
0.0%
6 Months
-6.91%
-7.2%
0.0%
1 Year
-55.92%
-11.1%
0.0%
3 Years
-48.38%
5.5%
-10.0%

Autolus Therapeutics Plc Key Stats

Check Autolus Therapeutics Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.75
Open
$1.79
Today's High
$1.77
Today's Low
$1.655
Market Capitalization
$465.7M
Today's Volume
$1.3M
52 Week High
$5.0
52 Week Low
$1.105
Revenue TTM
$29.9M
EBITDA
$-261.3M
Earnings Per Share (EPS)
$-0.87
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-52.11%

Stock Returns calculator for Autolus Therapeutics Plc Stock including INR - Dollar returns

The Autolus Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Autolus Therapeutics Plc investment value today

Current value as on today

₹46,169

Returns

₹53,831

(-53.83%)

Returns from Autolus Therapeutics Plc Stock

₹58,186 (-58.19%)

Dollar Returns*

₹4,355 (+4.36%)

Indian investors sentiment towards Autolus Therapeutics Plc Stock

7%

Period: Jul 26, 2025 to Aug 25, 2025. Change in 30 Days versus previous period

Search interest for Autolus Therapeutics Plc Stock from India on INDmoney has increased by 7% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Autolus Therapeutics Plc

  • Name

    Holdings %

  • Wellington Management Company LLP

    10.20%

  • Blackstone Inc

    7.70%

  • Mak Capital One LLC

    6.37%

  • Deep Track Capital, LP

    6.33%

  • Syncona Portfolio Ltd.

    6.25%

  • Armistice Capital, LLC

    4.51%

Analyst Recommendation on Autolus Therapeutics Plc Stock

Rating
Trend

Buy

    82%Buy

    17%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Autolus Therapeutics Plc(by analysts ranked 0 to 5 stars)

Autolus Therapeutics Plc Share Price Target

What analysts predicted

Upside of 479.65%

Target:

$9.62

Current:

$1.66

Autolus Therapeutics Plc share price target is $9.62, a slight Upside of 479.65% compared to current price of $1.66 as per analysts' prediction.

Autolus Therapeutics Plc Stock Insights

  • Price Movement

    In the last 7 days, AUTL stock has moved down by -6.9%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 29.0K → 20.92M (in $), with an average increase of 78.4% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -70.16M → -47.91M (in $), with an average increase of 46.4% per quarter
  • AUTL vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 122.8%
  • AUTL vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 162.8%
  • Price to Sales

    ForAUTL every $1 of sales, investors are willing to pay $15.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Autolus Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Autolus Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Autolus Therapeutics Plc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Autolus Therapeutics Plc logo
-30.28%
-6.91%
-55.92%
-48.38%
-88.96%
Regeneron Pharmaceuticals, Inc. logo
5.52%
-17.35%
-50.85%
-1.12%
-3.68%
Beone Medicines Ltd logo
6.51%
21.35%
57.45%
73.21%
25.84%
Vertex Pharmaceuticals Incorporated logo
-14.26%
-17.97%
-18.13%
40.27%
45.64%
Alnylam Pharmaceuticals, Inc. logo
39.9%
82.53%
68.83%
115.41%
241.51%

About Autolus Therapeutics Plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Organization
Autolus Therapeutics Plc
Employees
647
CEO
Dr. Christian Martin Itin Ph.D.
Industry
Health Technology

Key Management of Autolus Therapeutics Plc

NameTitle
Dr. Christian Martin Itin Ph.D.
CEO & Director
Mr. Alex Driggs
Senior VP of Legal Affairs & General Counsel and Secretary
Dr. Christopher Williams
Chief Business Officer
Dr. Matthias Will M.D.
Senior VP & Chief Development Officer
Dr. Martin Pule M.D., MBBS
Founder, Senior VP & Chief Scientific Officer
Mr. Robert F. Dolski
Senior VP, CFO & Principal Accounting Officer
Mr. Christopher Vann
Senior VP & COO
Mr. David Brochu
Senior VP & Chief Technical Officer
Ms. Olivia Manser
Director of Investor Relations
Mr. Alexander Swan
Senior VP & Chief Human Resources Officer

Important FAQs about investing in AUTL Stock from India :

What is Autolus Therapeutics Plc share price today?

Autolus Therapeutics Plc share price today is $1.66 as on . Autolus Therapeutics Plc share today touched a day high of $1.77 and a low of $1.66.

What is the 52 week high and 52 week low for Autolus Therapeutics Plc share?

Autolus Therapeutics Plc share touched a 52 week high of $5.00 and a 52 week low of $1.11. Autolus Therapeutics Plc stock price today i.e. is trending at $1.66, lower by 66.8% versus the 52 week high.

How to invest in Autolus Therapeutics Plc Stock (AUTL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Autolus Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Autolus Therapeutics Plc Shares that will get you 0.9036 shares as per Autolus Therapeutics Plc share price of $1.66 per share as on August 26, 2025 at 12:45 AM IST.

What is the minimum amount required to buy Autolus Therapeutics Plc Stock (AUTL) from India?

Indian investors can start investing in Autolus Therapeutics Plc (AUTL) shares with as little as ₹87.554 or $1 (as of August 26, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.54 in Autolus Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on August 26, 2025). Based on Autolus Therapeutics Plc share’s latest price of $1.66 as on August 26, 2025 at 12:45 AM IST, you will get 6.0241 shares of Autolus Therapeutics Plc. Learn more about fractional shares .

What are the returns that Autolus Therapeutics Plc has given to Indian investors in the last 5 years?

Autolus Therapeutics Plc stock has given -88.96% share price returns and 18.05% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?